Literature DB >> 28356979

Inhibition of store-operated Ca2+ entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.

Wei Huang1, Caiping Ren2, Guoling Huang2, Jie Liu2, Weidong Liu2, Lei Wang2, Bin Zhu2, Xiangling Feng2, Jia Shi2, Jinlong Li2, Xiaomeng Xia3, Wei Jia2, Jiawen Chen2, Yuxiang Chen4, Xingjun Jiang5.   

Abstract

Sodium butyrate (NaBu), a histone deacetylase inhibitor, has demonstrated anti-tumor effects in several cancers, and is a promising candidate chemotherapeutic agent. However, its roles in nasopharyngeal carcinoma (NPC), an endemic malignant disease in Southern China and Southeast Asia, has rarely been studied. In the present study, MTT assay, colony formation assay, flow cytometry analysis and western blotting were performed to explore the influence of NaBu on NPC cells and its underlying mechanism. NaBu induced morphological changes and inhibited proliferation in 5-8F and 6-10B cells. MTT assay revealed that NaBu was cytotoxic to 5-8F and 6-10B cells in a dose- and time-dependent manner. Furthermore, flow cytometry analysis revealed that NaBu induced obvious cell apoptosis in 5-8F and 6-10B cells due to the activation of the mitochondrial apoptosis axis. In addition, flow cytometry analysis and western blotting demonstrated that NaBu could enhance the Ca2+ influx by promoting store-operated Ca2+ entry (SOCE) in 5-8F and 6-10B cells. Inhibition of SOCE by specific inhibitors or downregulated expression of calcium release-activated calcium channel protein 1 and stromal interaction molecule 1 could counteract the apoptosis of NPC cells induced by NaBu. Thus, the current study revealed that enhanced SOCE and activated mitochondrial apoptosis axis may account for the mechanisms of cytotoxicity of NaBu in NPC cells, and that NaBu serves as a promising chemotherapeutic agent in NPC therapy.

Entities:  

Keywords:  SOCE; mitochondrial apoptosis; nasopharyngeal carcinoma; sodium butyrate

Year:  2016        PMID: 28356979      PMCID: PMC5351044          DOI: 10.3892/ol.2016.5469

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells.

Authors:  Dhanir Tailor; Eun-Ryeong Hahm; Raosaheb K Kale; Shivendra V Singh; Rana P Singh
Journal:  Mitochondrion       Date:  2013-10-29       Impact factor: 4.160

Review 3.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

Review 4.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  The inhibitor of histone deacetylases sodium butyrate enhances the cytotoxicity of mitomycin C.

Authors:  Anastas Gospodinov; Stanislava Popova; Ivelina Vassileva; Boyka Anachkova
Journal:  Mol Cancer Ther       Date:  2012-08-13       Impact factor: 6.261

6.  Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.

Authors:  Wilko Weichert; Annika Röske; Silvia Niesporek; Aurelia Noske; Ann-Christin Buckendahl; Manfred Dietel; Volker Gekeler; Markus Boehm; Thomas Beckers; Carsten Denkert
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

Review 7.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

8.  Enhancement of sodium butyrate-induced cell death and apoptosis by X-irradiation in the human colorectal cancer cell line HCT 116.

Authors:  Zheng-Li Wei; Qing-Li Zhao; Da-Yong Yu; Mariame A Hassan; Takaharu Nomura; Takashi Kondo
Journal:  Oncol Rep       Date:  2008-08       Impact factor: 3.906

Review 9.  Calcium and apoptosis: facts and hypotheses.

Authors:  Rosario Rizzuto; Paolo Pinton; Davide Ferrari; Mounia Chami; György Szabadkai; Paulo J Magalhães; Francesco Di Virgilio; Tullio Pozzan
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  6 in total

1.  l-ornithine activates Ca2+ signaling to exert its protective function on human proximal tubular cells.

Authors:  Samuel Shin; Farai C Gombedza; Bidhan C Bandyopadhyay
Journal:  Cell Signal       Date:  2019-11-23       Impact factor: 4.315

2.  Cardiomyocyte Stim1 Deficiency Exacerbates Doxorubicin Cardiotoxicity by Magnification of Endoplasmic Reticulum Stress.

Authors:  Jiang Zhu; Xia Zhang; Hong Xie; Yuye Wang; Xiaoxiao Zhang; Zhaoheng Lin
Journal:  J Inflamm Res       Date:  2021-08-14

3.  Suppression of Stim1 reduced intracellular calcium concentration and attenuated hypoxia/reoxygenation induced apoptosis in H9C2 cells.

Authors:  Fei He; Qianfu Wu; Banglong Xu; Xiaocheng Wang; Jixiong Wu; Li Huang; Jing Cheng
Journal:  Biosci Rep       Date:  2017-11-23       Impact factor: 3.840

4.  Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.

Authors:  Michael P Marciel; Vedbar S Khadka; Youping Deng; Pascal Kilicaslan; Andrew Pham; Pietro Bertino; Katie Lee; Suzie Chen; Natalija Glibetic; FuKun W Hoffmann; Michelle L Matter; Peter R Hoffmann
Journal:  Oncotarget       Date:  2018-02-03

5.  Time-dependent modulation of FoxO activity by HDAC inhibitor in oncogene-transformed E1A+Ras cells.

Authors:  Alisa Morshneva; Olga Gnedina; Svetlana Svetlikova; Valery Pospelov; Maria Igotti
Journal:  AIMS Genet       Date:  2018-02-08

Review 6.  Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma.

Authors:  Yuanbo Kang; Weihan He; Caiping Ren; Jincheng Qiao; Qiuyong Guo; Jingyu Hu; Hongjuan Xu; Xingjun Jiang; Lei Wang
Journal:  Signal Transduct Target Ther       Date:  2020-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.